News

Stock Movers: Novo Nordisk, Palo Alto, Union Pacific

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Novo Nordisk Stock Dives 20%. Ozempic Maker Unveils New CEO Amid Shock Cut to U.S. Outlook.

The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...

Ozempic maker Novo Nordisk on track for its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

European stocks close up; Novo Nordisk logs its biggest daily drop on record

European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest ...

Don't buy the dip in Novo Nordisk yet, says Mizuho's Jared Holz

Jared Holz, Mizuho health care equity strategist, joins 'Money Movers' to discuss Novo Nordisk sinking on guidance cut and ...
Explore more

Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

Novo Lifer Takes Job of Reviving Europe’s Weight-Loss Superstar

Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through ...